Vertero Therapeutics, Inc. has completed patient enrollment in its Phase 1b study of VT-5006, a first-in-class treatment for Parkinson’s...
Read more
The Gut Microbiome May Unlock New Treatment Paradigms For Neurological Diseases – Axial Therapeutics
Autistic children have long been known to have differences in their gut microbiota and as a result are more...
Read more
Axial Therapeutics announced completion of enrollment in the TAPESTRY Autism Study, the Phase 2b clinical trial of its lead...
Read more
Axial Therapeutics announced it has received a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF)...
Read more
Axial Therapeutics announced it is expanding the age eligibility criterion to include children ages 5 to 17 years in...
Read more
Axial Therapeutics announced key promotions in its research and development organization. These promotions recognize the Axial team’s scientific and...
Read more
A new trial sponsored by Axial Therapeutics will test whether a medication that targets gut bacteria can also improve...
Read more
Axial Therapeutics announced that A. Stewart Campbell, Ph.D., chief executive officer, will give a presentation titled, “Targeting Bacterial Metabolites...
Read more
Axial Therapeutics announced that it is building on its clinical development science and operations capabilities through recent key appointments....
Read more
Axial Therapeutics Inc. announced that A. Stewart Campbell, Ph.D., Chief Executive Officer, will present in two seminars at BioJapan...
Read more